CSF p-tau217 normalizes before amyloid PET reaches cessation thresholds because p-tau217 reflects active neuronal pathology while amyloid PET measures accumulated plaques. This temporal disconnect means p-tau217 normalization may identify the critical window when ongoing amyloid-driven neurodegeneration has ceased, potentially allowing treatment cessation before complete amyloid clearance. The faster decline kinetics of p-tau217 compared to amyloid PET offer practical clinical utility for reducing ARIA risk, treatment burden, and cost.
Curated pathway from expert analysis
flowchart TD
A["Active Neuronal<br/>Pathology"]
B["CSF p-tau217<br/>Elevation"]
C["Amyloid PET<br/>Accumulates"]
D["PET Cessation<br/>Threshold"]
E["p-tau217<br/>Normalization"]
F["Earlier Cessation<br/>Decision"]
A --> B
A --> C
C --> D
B --> E
E --> F
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style B fill:#e65100,stroke:#ffab91,color:#ffab91
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for N yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for N.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF participants receiving anti-amyloid immunotherapy (lecanemab, donanemab, or aducanumab) are monitored with concurrent CSF p-tau217 and amyloid PET measurements at 3-month intervals for 36 months, T | Median time to CSF p-tau217 normalization will be at least 6 months shorter than median time to amyloid PET negativity, with >70% of participants showing this t | — no observation — | pending | 0.65 |
| IF participants who achieve CSF p-tau217 normalization are randomized to immediate treatment cessation versus continued treatment for 24 additional months, THEN the immediate cessation group will demo | Immediate cessation group based on p-tau217 normalization shows mean 12-month CDR-SB change ≤0.5 points worse than continued treatment group, confirming identif | — no observation — | pending | 0.45 |